Mineralocorticoid receptor antagonists (MRAs) reduced the risk of cardiovascular death or heart failure (HF) hospitalization in patients with HF and reduced ejection fraction (HFrEF) and also in those ...

In a recent meta-analysis published in The Lancet, researchers investigated the effect of steroidal and nonsteroidal mineralocorticoid receptor antagonists (MRAs) on patients with heart failure (HF) ...

Please provide your email address to receive an email when new articles are posted on . An updated clinical practice guideline suggested screening all people with hypertension for primary ...

QUEBEC CITY — The Canadian Cardiovascular Society (CCS) has updated its guidelines on the management of heart failure (HF) with nonreduced ejection fraction (HFnrEF), highlighting the role that SGLT2 ...

London, United Kingdom – 1 September 2024: Mineralocorticoid receptor antagonists (MRAs) reduced the risk of cardiovascular death or heart failure (HF) hospitalisation in patients with HF and reduced ...

The year saw the emergence of a new version of an old drug that proved beneficial in patients who have heart failure with ...

What if there were a straightforward and relatively inexpensive way to lower the incidence of heart failure (HF), renal disease, stroke, and cognitive impairment? Cardiologist Bertram Pitt, MD, said ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced. The nonsteroidal mineralocorticoid receptor antagonist (MRA) is the first of its ...